Pelthos TherapeuticsPTHS
13F holders, Q3 2025 (September 30)14holders
$28.00avg. 13F price*
At the end of Q3 2025, 14 institutions reported holding Pelthos Therapeutics Inc. (PTHS) in their 13F filings. The largest holders were Murchinson Ltd. ($7.8M), Vanguard Group Inc. ($1.9M) and Ikarian Capital, LLC ($1.7M).
- Company
- Pelthos Therapeutics Inc.
- CUSIP
- 171126204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 14 | $13.0M |
| Exits | 0 | $0 |
Ownership 14 holders
| Murchinson Ltd. | 1.55% | New | 280,000 | $7.8M |
| Vanguard Group Inc. | 0.00% | New | 66,836 | $1.9M |
| Ikarian Capital, LLC | 0.35% | New | 62,451 | $1.7M |
| Boothbay Fund Management, LLC | 0.02% | New | 21,245 | $595K |
| Diadema Partners LP | 0.20% | New | 10,498 | $294K |
| Geode Capital Management, LLC | 0.00% | New | 10,330 | $289K |
| Knott David M Jr | 0.07% | New | 6,112 | $171K |
| Persistent Asset Partners Ltd | 0.05% | New | 2,403 | $67K |
| Steward Partners Investment Advisory, LLC | 0.00% | New | 1,910 | $53K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 827 | $23K |
| UBS Group AG | 0.00% | New | 137 | $4K |
| Bank of America Corp. | 0.00% | New | 11 | $308 |
| JPMorgan Chase & Co. | 0.00% | New | 1 | $28 |
| Citigroup Inc. | 0.00% | New | 1 | $28 |
"% of holder's portfolio" is PTHS's weight in each manager's 13F, not the share of Pelthos Therapeutics Inc. the manager owns.